{"entity":{"id":"nct07829549","kind":"trial","name":"Phase III Study of RC148 Plus Chemotherapy Versus Tislelizumab Plus Chemotherapy as First-Line Treatment for Non-Squamous Non-Small Cell Lung Cancer Without Act","aka":[],"tldr":"A phase 3 trial of carboplatin and tislelizumab in lung cancer, run by RemeGen Co., Ltd., not yet recruiting.","summary":"Phase III Study of RC148 Plus Chemotherapy Versus Tislelizumab Plus Chemotherapy as First-Line Treatment for Non-Squamous Non-Small Cell Lung Cancer Without Actionable Genomic Alterations is a phase 3, randomised interventional study registered as NCT07829549 by RemeGen Co., Ltd., with a registry enrolment figure of 540 participants, started 2026-09-30 and due to reach its primary completion in 2031-04. Interventions recorded: RC148 Injection plus Pemetrexed Disodium for Injection and Carboplatin Injection; Tislelizumab Injection plus Pemetrexed Disodium for Injection and Carboplatin Injection. Conditions listed: Previously Untreated Locally Advanced (IIIB/IIIC) or Metastatic (IV) e Nsq NSCLC Without Actionable Genomic Alterations. Primary outcome: Progression-Free Survival assessed by BIRC per RECIST v1.1. Lung eligibility wording from the registry: \"Histologically or cytologically confirmed locally advanced or metastatic NSCLC, not amenable to curative-intent therapy\". Sites: China. No results are recorded here; the registry entry is the source.","status":"planned","asOf":"2026-09-25","links":[{"label":"ClinicalTrials.gov NCT07829549","url":"https://clinicaltrials.gov/study/NCT07829549"}],"tags":["ctgov-ingest","lung-deep-dive"],"related":[],"cancers":["nsclc"],"sections":[],"technologies":["checkpoint-inhibitor","cytotoxic-chemotherapy","platinum"],"targets":[],"drugs":["carboplatin","tislelizumab"],"companies":["remegen"],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"nct":"NCT07829549","phase":"3","setting":"A Randomized, Double-blind, Multicenter Phase III Study of RC148 Combined With Platinum-Based Chemotherapy Versus Tislelizumab Combined With Platinum-Based Chemotherapy as First-Line Treatment for Advanced Nonsquamous Non-Small Cell Lung Cancer Without Actionable Genomic Alterations","sponsor":"RemeGen Co., Ltd.","enrolled":540,"enrolledBasis":"registry","outcomes":[]},"route":"/trials/nct07829549/","neighbours":{"cancer":[{"id":"nsclc","kind":"cancer","name":"Non-small-cell lung cancer","route":"/cancers/nsclc/"}],"technology":[{"id":"cytotoxic-chemotherapy","kind":"technology","name":"Cytotoxic chemotherapy","route":"/technologies/cytotoxic-chemotherapy/"},{"id":"checkpoint-inhibitor","kind":"technology","name":"Immune checkpoint inhibitors","route":"/technologies/checkpoint-inhibitor/"},{"id":"platinum","kind":"technology","name":"Platinum agents","route":"/technologies/platinum/"}],"drug":[{"id":"carboplatin","kind":"drug","name":"Carboplatin","route":"/drugs/carboplatin/"},{"id":"tislelizumab","kind":"drug","name":"Tislelizumab","route":"/drugs/tislelizumab/"}],"company":[{"id":"remegen","kind":"company","name":"RemeGen","route":"/companies/remegen/"}],"term":[{"id":"lung-trials-open-today","kind":"term","name":"Lung cancer trials open today (registry snapshot)","route":"/terms/lung-trials-open-today/"}]}}